key: cord-0865556-ka9qa918
authors: van Dam, Peter; Huizing, Manon; Roelant, Ella; Hotterbeekx, An; De Winter, Fien HR.; Kumar-Singh, Samir; Moons, Pieter; Amajoud, Zainab; Vulsteke, Christof; Croes, Lieselot; Janssens, Annelies; Berneman, Zwi; Prenen, Hans; Meuris, Leander; Berghe, Wim Vanden; Smits, Evelien; Peeters, Marc
title: Immunoglobin G / total antibody testing for SARS-CoV-2: a prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing 3 commercial tests
date: 2021-02-27
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2021.02.024
sha: ad2c6b7ce8bf37592b487cfc1e31c46aa77d61e2
doc_id: 865556
cord_uid: ka9qa918

BACKGROUND: Coronavirus disease (COVID-19) is interfering heavily with the screening, diagnosis and treatment of cancer patients. Better knowledge of the seroprevalence and immune response after Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in this population is important to manage them safely during the pandemic. METHODS: 922 cancer patients, 100 non-cancer patients and 94 healthcare workers (HCW) attending the Multidisciplinary Oncology Unit of Antwerp University Hospital from 24(th) of March 2020 till 31(st) of May 2020, and in the Oncology Unit of AZ Maria Middelares Hospital Gent from 13(th) of April 2020 till 31(st) of May 2020 participated. The Alinity® (A; Abbott) and Liaison® (D; Diasorin) commercially available assays were used to measure SARS-CoV-2 IgG, while total SARS-CoV-2 Ig was measured by Elecsys® (R; Roche) RESULTS: In the overall study population IgG/total SARS-CoV-2 antibodies were found in respectively 32/998 (3.2%), 68/1020(6.7%), 37/1010 (3.7%) and of individuals using the A, D or R test. Forty six out of 618 (7.4%) persons had a positive SARS-CoV-2 polymerase chain reaction (RT-PCR) test. Seroprevalence in cancer patients (A:2.2%, D:6.2%, R:3.0%), did not significantly differ from that in non-cancer patients (A:1.1%, D:5.6%, R:0.0%), but was lower than the HCW (A:13%, D:12%, R:12%; respectively Fisher’s exact test p=0.00001, p=0.046, p=0.0004). A positive SARS-CoV-2 RT-PCR was found in 6.8% of the cancer patients, 2.3% of the non-cancer patients and 28.1% of the HCW (Fisher’s exact test p=0.0004). Correlation between absolute value of the different Ig tests was poor in the cancer population. Dichotomizing a positive versus negative test result, the A and R test correlated well (kappa 0.82 p McNemar test=0.344), while A and D, and R and D did not (respectively kappa 0.49 and 0.57; result significantly different p McNemar test=<0.0001 for both). The rate of seroconversion (>75%) and median absolute antibody levels (A: 7.0 vs 4.7; D 74.0 vs 26.6, R: 16.34 vs 7.32; all > P Mann Whitney test=0.28) in cancer patients and HCW with a positive RT-PCR at least 7 days earlier did not show any differences. However, none (N=0/4) of the patients with hematological tumors had seroconversion and absolute antibody levels remained much lower compared to patients with solid tumors (R: 0.1 vs 37.6, p 0.003; D 4.1 vs 158, p 0.008) or HCW (all p<0.0001). CONCLUSION: HCW were at high risk to be infected by SARS-CoV-2 during the first wave of the pandemic. Seroprevalence in cancer patients was low in the study period. Although Ig immune response in cancer patients with solid tumors does not differ from healthy volunteers, patients with hematological tumors have a very poor humoral immune response. This has to be taken into account in future vaccination programs in this population. SARS-CoV-2 antibody tests have divergent results and seem to have little added value in the management of cancer patients.

Betacoronavirus. It was first reported after an outbreak of unusual pneumonia in the city of Wuhan, People's Republic on 31 st of December 2019 and shortly after declared to be a Public Health Emergency of International Concern [1] .

Unfortunately, today, the virus is widely spread throughout the world and declared by the WHO as a pandemic [2] . There is a broad range of clinical presentations of SARS-CoV-2 viral infection varying from asymptomatic, sensation of a mild cold or flu to severe bilateral pneumonia and death [1] [2] [3] [4] . The evolution of COVID-19 depends not only on the pathogen but also on the genetic and epigenetic background of the host [5] . Apoptosis and/or dysfunctions of (cancer) immune cells and complex epigenetic reprogramming in immune and progenitor cells may contribute to the immunoparalysis and/or opportunistic co-infections in COVID-19 patients [5] [6] . The mortality is the highest in the elderly and in people with a pre-existing condition such as cardio-vascular disease, pulmonary disease, inflammatory disorders, hypertension, diabetes and particularly in cancer patients with active disease and (a history of) hematological tumors [6] [7] . Ambiguity remains over differences in the expected acquired immunity, and its duration in these different populations [6] .

Understanding both the rate of asymptomatic infection and pre-existing immunity is key to assess potential impact of pandemic spread of this virus in a cancer patient community [8] . Important insights can be gained from serology studies to get data on the proportion of (asymptomatic) infected high-risk patients in a population . In addition, patients and health care workers may be identified that are potentially protected from reinfection by neutralizing antibodies, although currently it is not certain if and how long immunity would be present [9] . On average IgM antibodies are detectable around 7 days after a SARS-CoV-2 infection. Immunoglobin G antibodies can be found in 75% of patients after 7 days and in about 90% after two weeks [8, 14] . As IgA and IgM antibodies often lack specificity and have a shorter half-life most serologic studies focus on IgG [8, [13] [14] [15] [16] [17] [18] [19] . The exact role of IgG antibodies in the immune response to SARS-CoV-2 is unclear but these antibodies often have a virus neutralizing capacity [9] . We present a prospective multicenter J o u r n a l P r e -p r o o f study evaluating three commercially available SARS-CoV-2 IgG/total Ig antibody tests on prospectively collected serum of ambulatory cancer and non-cancer patients and HCW in two Belgian oncology units during the rise, nadir and decline of the first peak SARS-CoV-2 epidemic.

Study objectives. The primary objective of the study was to document the prevalence and seroprevalence of SARS-CoV-2 IgG/total Ig in ambulatory patients and a group of healthcare workers (HCW) in two oncology units during and after community spread of the virus. Three commonly used commercially available SARS-CoV-2 IgG/total IG tests for SARS-Cov-2 were compared in both populations in a real-life context to assess their reliability. Secondary additional translational research will be conducted on the samples, which is not part of this manuscript.

Sample collection. After written informed consent, an additional 10 ml lithium heparin plasma, a 10 ml EDTA-tube and a 4 ml serum sample were collected prospectively at every clinically indicated blood sampling in cancer and non-cancer Hospital the study blood sample volume (heparin plasma, EDTA and serum) was decided by the treating physician according to the body weight of the patient, ranging from 9.5 ml to 24 ml in total, and these patients were sampled at intervals of at least 30 days. In addition, HCW from both participating units were asked to voluntarily donate similar blood samples at time points 0, 1, 2 and 3 months after the start of the study. Samples from the Oncology Unit of AZ Maria Middelares Hospital Gent were collected and labelled locally and transferred to the biobank of the Antwerp University Hospital. All samples were stored in the Biobank of Antwerp University Hospital at -20°C. They received a unique code in order to allow linkage to "source data".

Inclusion criteria. All (cancer) patients having a routine blood sampling and HCW consenting to participate in the study in the Multidisciplinary Oncology unit of the J o u r n a l P r e -p r o o f Antwerp University Hospital, the AZ Maria Middelares Hospital Gent. All paediatric cancer patients, having a routine blood sampling, whose parents or guardian consented to participate in the study in the Antwerp University Hospital at time points 0, 1, 2 and 3 months. Exclusion criteria. Critically ill patients or volunteers in which the consenting procedure of taking additional blood samples is not ethically and/or clinically acceptable. Treatment of the patients. As the SARS-CoV-2 antibody testing was performed as a batch in retrospect, the test results did not influence their clinical management.

Several mitigating risk strategies were implemented in routine cancer care from March 13 th onward. Non-urgent visits such as follow-ups were postponed or replaced by teleconsultation [10] . All oncologic systemic treatments were continued and administered on an outpatient basis when possible. A system for home monitoring for symptoms and treatment related side effects (AMTRA, Remedus) and home blood sampling (BAPIC) was routinely offered to all patients [10] [11] [12] . Both BAPIC and AMTRA were used for systematic toxicity and SARS-CoV-2 symptom registration [11, 12] . Visitation regulations were restrictive and social distancing was practiced as much as possible [11] . From March 31 st onward mask wearing was obligatory for patients and health care providers. Additional throat washing for PCR testing against SARS-CoV-2 every fortnight was implemented from April 14 th onward. 

The dataset contained 3650 samples in 1115 different subjects: 13 children, 908 cancer and 100 non-cancer patients, and 94 HCW. Three hundred seventy-nine of the cancer patients (41.7%) had a hematological tumor, the others a solid cancer (breast N=163, lung N=42, prostate cancer N=29 being the most frequent tumor types). Six children had a malignant hematological cancer and 7 a solid tumor. The HCW contained 91 non-oncological subjects, 2 oncological patients and 1 individual with a malignant hematological tumor. We considered the 3 latter in the cancer patient group. Details on the population characteristics are given in Table 1 

Test results for the entire population and different subgroups are given in Table 2 and in 

Correlation between absolute value of the different SARS-CoV-2 IgG/total antibody tests is given in Table 3 . In HCW the three tests correlated moderately well (kappa 0.39-0.53), while for the pediatric patients only a correlation could be found between A and R (kappa 0.68). In the cancer-and non-cancer patients, correlation between the 3 serological tests was absent or poor (kappa -0. 18 

It remains an unanswered question how accurate serologic tests for SARS-CoV-2 are in different populations and how they can be used in clinical practice to benefit the patients . The majority of commercially available tests against SARS-CoV-2 IgG are directed to recombinant antigens covering the viral nucleocapsid protein (Abbott, Roche) or the S1/S2 domain of the spike protein (Diasorin) [16] . They have been developed rapidly over the last half year and were often introduced in clinical settings before being validated with samples in larger cohorts [13] [14] [15] [16] [17] [18] [19] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . Estimates about seroprevalence of SARS-CoV-2 in cancer populations strongly depend on the type of serologic test used, the population tested (ambulatory versus hospitalized), and timing of testing particularly related to the extent of the COVID-19 pandemic in the local general population [6] . A summary of studies performed in cancer populations is given in Table 5 . Immunoglobulin G/total antibodies directed to SARS-CoV-2 during the first wave of the SARS-CoV-2 pandemic were low in our Major factors driving seropositivity are the type of hospital setting assessed, the job duties and patient contacts of the HCW, and the intensity of the COVID-19 pandemic in the area [42] . In a nationwide Scottish linkage cohorts study comprising 158,445 health care workers and 229,905 household members it was shown that patient facing health care workers and their household members respectively have a threefold and twofold increased risk of admission with serious COVID-19 [29] . Small studies in oncology units showed seroconversion rates of 5-7.5% amongst staff members [27, 28] . Health care professionals had a significantly higher prevalence of SARS-CoV-2 antibodies and RT-PCR confirmed SARS-CoV-2 infection compared to patients in our population. This can be explained by the lack of availability and suboptimal use of protective material until end-March 2020. We had an outbreak of COVID-19 in the oncology unit of the Antwerp University Hospital affecting some patients, medical and nursing staff before masks and protective clothing became generally available and obligatory to be used. This was managed successfully by closing the unit for a week, testing all patients and health care professionals for SARS-CoV-2 by PCR, sending all asymptomatic staff on leaf for a week and SARS-CoV-2 confirmed positive individuals for 2 weeks, isolating the involved patients and segregating pathways [10, 12] . In fact we did not have any problems afterwards.

However, this highlights the importance of protective measures in this population. Several small series have suggested that cancer patients had lower rates of seroconversion after clinical COVID-19 compared to non-cancer patients [30, 31, 32, 33] , but this could not be confirmed by others [34] . In the study of Mara et al, specifically focusing on SARS-CoV-2 seroconversion in cancer patients and oncology health care workers, no difference in SARS-CoV-2 IgG positivity was observed between both groups using 2019-nCoV IgG/IgM Rapid Test Cassette: respectively 25/29 (87.9%) vs 25/33 (80.5%; p=0.39) [26] . In addition, no differences in time from SARS-CoV-2 diagnosis to IgG detection was seen comparing cancer The Alinity ® (A; Abbott) and Liaison ® (D; Diasorin) commercially available assays were used to measure SARS-CoV-2 IgG, while total SARS-CoV-2 Ig was measured by Elecsys ® (R; Roche) 

A new coronavirus associated with human respiratory disease in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Clinical Characteristics of Coronavirus Disease 2019 in China

Determinants of COVID-19 disease severity in patients with cancer

CoV-2 and cancer: Are they really partners in crime?

OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million NHS patients

The role of antibody testing for SARS-CoV-2: is there one ?

Diagnostic accuracy of six commercial SAES-Cov-2 IgG/total antibody assays and identification of SARS-Cov-2 neutralizing antibodies in convalescent sera

Prescreening for COVID-19 in patients receiving cancer treatment using a patient-reported outcome platform

The tele-transition of toxicity management in routine oncology care during the SARS-CoV-2 pandemic

AMTRA: a multicentered experience of a web-based monitoring and tailored toxicity management system for cancer patients

Seroprevalence of SARs-CoV-2-specifica antibodies in cancer outpatients in Madid 5Spain): a single center, prospective cohort study and review of available data

Antibody tests in detecting SARS-CoV-2 infection: a metaanalysis

Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARSassociated coronavirus

Diagnostic accuracy of six commercial SAES-Cov-2 IgG/total antibody assays and identification of SARS-Cov-2 neutralizing antibodies in convalescent sera

Lack of peripheral memory B cell

responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study

Clinical performance of different SARS-CoV-2 IgG antibody tests

Heterogenous antibodies againts SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COV-19 immunity

Performance of an automated chemiluminescence SARS-CoV-2 IgG assay

Analytical and clinical evaluation of the automated Elecsys anti-SARS-Cov-2 antibody assay on the Roche cobas e602 analyzer

Evaluation of the Roche Elecsys anti-SRARS-CoV-2 assay

The National SARS-CoV-2 Serology Assay Evaluation Group. The performance characteristics of five immunoassays for SARS-CoV-2: a headto-head benchmark comparison

Comparative clinical evaluation of the Roch Elecsys and Abbott SARS-CoV-2 serology assays for COVID-19

Sars-Cov-2 seroprevalence in oncology health care professionals and patients with cancer

COVID-19 pandemic

Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2

Serological prevalence of antibodies to SARs-CoV-2 amongst cancer center staff

Seroprevalence of COVID-19 antibodies in the cleaning and oncological staff of a municipal clinic

Risk of hospital admission with coronavirus disease 2019 in health care workers and their households: nationwide linkage cohort study

Lower detection rates of SARS-COV2 antibodies in cancer patients vs healthcare workers after symptomatic COVID-19

Rare SARS-CoV-2 antibody development in cancer patients

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19

Seroprevalence of SARS-CoV-2 antibodies and associated factors in health care workers: a systematic review and metanalysis

Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals ins outhern switzerland. The Lancet Regional Health Europe

Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients

Pediatric cancer patients

Health care workers